Cancer: A Case of Good Design Turned Awry

01 · Deep time

Life evolved; cancer hitchhiked on the same code

Roughly 3.6 billion years separate single-celled marine life from land-walking vertebrates. Fish, jaws, cartilaginous and bony lineages, lobed fins on land, then amphibians, reptiles, mammals, and humans: each step was morphology under survival pressure.

To the oncologist, that deep-time sketch is not a nature documentary. It is gene mutation at work: the same process that can, without restraint, drive malignancy inside one lifespan.

04 · Multi-hit and age

Not every mutation becomes cancer

As a rule of thumb, malignancy usually needs multiple mutations, often a double-digit count, before a cell turns possibly cancerous. An inherited defect counts as one predisposing hit, not the whole story. Time is therefore a precondition, which is why cancer is so often a disease of older age.

Beyond sporadic outside assaults on DNA, ordinary self-renewal can introduce progressive errors when replication accuracy slips. The body replaces about 330 billion cells daily. Division is like photocopying the same page again and again: sharpness drifts. Random transcription or replicative errors that alter DNA are inevitable at that scale.

According to the National Cancer Institute, the average age of people first diagnosed with cancer in 2020 framing is about 66: roughly half of cases arise at 66 or older, and risk keeps rising with age. Live long enough and the odds of a clinically important mutation stack become hard to ignore.

05 · Mutation types and defences

Somatic vs germline, TP53, and telomeres

Mutations fall into two major classes. Germline refers to reproductive cells; all other cells are somatic. DNA damage that is not repaired in non-replicating cells mainly accelerates ageing. The same unrepaired damage in replicating cells or stem cells can become a lasting mutation. Germline mutations arise in gametes and can pass to offspring, with every cell of that child carrying the change. Only about 2% of DNA codes for genes, so many sporadic alterations never touch functional sequence and remain harmless.

The mutations that count toward malignancy are those in oncogenes, tumour-suppressor genes, or cell-cycle controllers that create a clonal population with a clear proliferative advantage. Cells are not defenceless. Tumour-suppressor and immune systems repair or arrest DNA damage and, when damage is irreparable, can end the cell through apoptosis (programmed cell death).

The TP53 gene instructs production of tumour protein p53, often called the guardian of the genome. As a tumour suppressor, p53 keeps cells from growing and dividing without control. Telomeres at both ends of each chromosome maintain chromosomal stability and limit how many times a cell can divide. That replication ceiling is another brake on malignant proliferation.

06 · Three triggers

Hereditary, environmental, and replicative

Across 32 cancer types, Tomasetti, Li, and Vogelstein (2017) attributed cancer-promoting mutations roughly as below. Organ patterns still deviate: pancreatic cancers lean replicative; lung cancers lean environmental.

07 · Apoptosis story

Fingers, toes, and what happens when death programmes fail

Early in gestation, human embryonic fingers and toes are webbed, a quiet echo of aquatic ancestry. Before about the eighth week, connecting tissue dissolves and separate digits emerge through apoptosis, guided in part by Sonic Hedgehog signalling. Babies born with fused digits have syndactyly, a failure of that programme.

Loss of apoptosis that leaves cells effectively immortal is one of the principal routes into cancer. Life holds mechanisms that are elegant when they work and costly when they fail. This opinion only opens the door. Going deeper will be more demanding; the storyteller’s job, in Einstein’s words, is to make it as simple as possible but no simpler.

Continue with modifiable lifestyle risk, contemporary treatment options, and TCM alongside cancer care.